SCHEMBL864044

SCHEMBL864044

Clc1ccc(-c2ccc3[nH]ccc3c2)nn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 4/20 0.50
AHR P35869 3/20 0.50
NR4A2 P43354 2/20 0.50
F7 P08709 1/20 0.50
LTA4H P09960 1/20 0.50
F3 P13726 1/20 0.50
DYRK3 O43781 1/20 0.50
CCNT1 O60563 1/20 0.50
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50
CDK9 P50750 1/20 0.50
CDK5 Q00535 1/20 0.50
DYRK1A Q13627 1/20 0.50
CDK5R1 Q15078 1/20 0.50
DYRK2 Q92630 1/20 0.50
DYRK1B Q9Y463 1/20 0.50
NPC1 O15118 1/20 0.50
KCNH2 Q12809 1/20 0.47
GUSB P08236 3/20 0.46
FYN P06241 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3463084 0.80 CHRNA7 (0.50) CHRNA7AHRNR4A2F7LTA4H
SCHEMBL5850255 0.75 NPC1 (0.79) AHRNR4A2F7LTA4HF3
SCHEMBL3364409 0.74 HSP90AA1 (0.54) AHRNR4A2F7LTA4HF3
SCHEMBL13745078 0.74 GUSB (0.66) CHRNA7NPC1KCNH2GUSBFYN
SCHEMBL4486564 0.73 AHR (0.70) CHRNA7AHRNR4A2F7LTA4H
SCHEMBL3400660 0.72 AHR (0.49) AHRNR4A2F7LTA4HF3
SCHEMBL2275275 0.72 AHR (0.62) CHRNA7AHRNR4A2F7LTA4H
SCHEMBL12676739 0.71 NPC1 (0.51) CHRNA7AHRNR4A2F7LTA4H
SCHEMBL22259510 0.71 CHRNA7 (0.46) CHRNA7NPC1KCNH2GUSBFYN
SCHEMBL31072376 0.71 CHRNA7 (0.46) CHRNA7DYRK3CCNT1CDK9CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed
EP-2406264-A2 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS The Regents of The University of California (US) 2012-01-18 EP disclosed
WO-2010104843-A2 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS CHRNA7, CHRNA5, CHRNA1 CHRNA7 1/4885AHR 795/4885NR4A2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.